Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16).
Ribi K, Thürlimann B, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R, Mark M. Ribi K, et al. Among authors: anchisi s. BMC Cancer. 2021 Feb 19;21(1):182. doi: 10.1186/s12885-021-07903-8. BMC Cancer. 2021. PMID: 33607966 Free PMC article.
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03).
Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M, Stupp R. Pesce GA, et al. Among authors: anchisi s. Eur J Cancer. 2012 Feb;48(3):377-84. doi: 10.1016/j.ejca.2011.10.016. Epub 2011 Nov 15. Eur J Cancer. 2012. PMID: 22093943 Clinical Trial.
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Koeberle D, Betticher DC, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Frueh M, Kueng M, Popescu RA, Schacher S, Hess V, Herrmann R. Koeberle D, et al. Among authors: anchisi s. Ann Oncol. 2015 Apr;26(4):709-714. doi: 10.1093/annonc/mdv011. Epub 2015 Jan 20. Ann Oncol. 2015. PMID: 25605741 Free article. Clinical Trial.
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK). Rochlitz C, et al. Among authors: anchisi s. BMC Cancer. 2016 Oct 10;16(1):780. doi: 10.1186/s12885-016-2823-y. BMC Cancer. 2016. PMID: 27724870 Free PMC article. Clinical Trial.
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
Rothschild SI, Betticher D, Zenhäusern R, Anchisi S, von Moos R, Pless M, Moosmann P, Popescu RA, Calderoni A, Dressler M, Rauch D, Pederiva S, Woelky R, Papet C, Bühler V, Borner M. Rothschild SI, et al. Among authors: anchisi s. Cancer Chemother Pharmacol. 2019 Oct;84(4):881-889. doi: 10.1007/s00280-019-03927-x. Epub 2019 Aug 23. Cancer Chemother Pharmacol. 2019. PMID: 31444619 Free PMC article.
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).
Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R. Mark M, et al. Among authors: anchisi s. J Bone Oncol. 2019 Dec 16;21:100273. doi: 10.1016/j.jbo.2019.100273. eCollection 2020 Apr. J Bone Oncol. 2019. PMID: 31970055 Free PMC article.
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
Stoffel ST, von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-Härdi U, von Briel T, Anchisi S, Feller A, Schär C, Dietrich D, Schwenkglenks M, Lupatsch JE, Mark MT. Stoffel ST, et al. Among authors: anchisi s. Swiss Med Wkly. 2021 Mar 1;151:w20464. doi: 10.4414/smw.2021.20464. eCollection 2021 Mar 1. Swiss Med Wkly. 2021. PMID: 33705559 Free article.
Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study.
Hofheinz RD, Anchisi S, Grünberger B, Derigs HG, Zahn MO, Geffriaud-Ricouard C, Gueldner M, Windemuth-Kieselbach C, Pederiva S, Bohanes P, Scholten F, Piringer G, Thaler J, von Moos R. Hofheinz RD, et al. Among authors: anchisi s. Cancers (Basel). 2022 Jul 20;14(14):3522. doi: 10.3390/cancers14143522. Cancers (Basel). 2022. PMID: 35884583 Free PMC article.
Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment.
Betticher DC, Delmore G, Breitenstein U, Anchisi S, Zimmerli-Schwab B, Müller A, von Moos R, Hügli-Dayer AM, Schefer H, Bodenmann S, Bühler V, Trueb RR. Betticher DC, et al. Among authors: anchisi s. Support Care Cancer. 2013 Sep;21(9):2565-73. doi: 10.1007/s00520-013-1804-9. Epub 2013 May 2. Support Care Cancer. 2013. PMID: 23636645 Clinical Trial.
55 results